Luisa Munoz Del Romeral, MD
Cardiovascular Disease (Cardiology) · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · Berkeley Cardiovascular Medical Group
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Romeral’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A63860 · Current
Licensed to practise in California · since 1997 · expires 2027-11-30 · University of Valladolid Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$127,564
Medicare paid this office $127,564 for 554 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 125 | $32,998 | $156 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $21,514 | $205 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $18,161 | $112 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 200 | $13,217 | $65 |
| Return visit (30+ min) | 77 | $10,553 | $110 |
See all 23 services
| Long return visit (40+ min) | 125 | $32,998 | $156 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $21,514 | $205 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $18,161 | $112 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 200 | $13,217 | $65 |
| Return visit (30+ min) | 77 | $10,553 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,432 | $161 |
| Critical care, first 30-74 minutes | 19 | $6,095 | $197 |
| New patient visit (60+ min) | 26 | $4,723 | $182 |
| Ultrasound of both sides of head and neck blood flow | 12 | $2,183 | $182 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 131 | $2,007 | $13 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,394 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,194 | $75 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 59 | $1,187 | $20 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 17 | $1,107 | $65 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 59 | $778 | $13 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 17 | $371 | $22 |
| 3d ultrasound imaging of heart for evaluation of heart structure performed during ultrasound imaging of congenital heart defects | 14 | $324 | $22 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 12 | $289 | $24 |
| Ultrasound of heart, follow-up | 12 | $281 | $23 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $235 | $17 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 17 | $224 | $13 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $80 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $35 | $3 |
Who their Medicare patients are
554 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 21% · Women 53% · Also on Medicaid 32% · Health risk score 1.71. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Chronic kidney disease 40% · Coronary heart disease 38% · Heart failure 38% · Diabetes 37% · Atrial fibrillation 36% · Depression 22% · Cancer 20% · Stroke 19% · COPD 16% · Dementia 11%.
The office billed $373,630, Medicare allowed $166,489 and paid $127,564; for 1,359 services of 34 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 554 | 1,359 | 77 | 1.71 | $373,630 | $127,564 |
| 2023 | 657 | 1,594 | 76 | 1.84 | $410,129 | $130,024 |
| 2022 | 735 | 1,861 | 76 | 1.92 | $526,314 | $163,113 |
| 2021 | 797 | 1,907 | 75 | 1.99 | $555,492 | $171,572 |
| 2020 | 713 | 1,645 | 74 | 2.11 | $488,250 | $146,505 |
| 2019 | 1,030 | 2,382 | 75 | 1.86 | $763,464 | $227,807 |
| 2018 | 790 | 1,853 | 74 | 1.88 | $665,863 | $181,547 |
| 2017 | 694 | 1,810 | 75 | 1.86 | $650,233 | $179,904 |
| 2016 | 727 | 1,819 | 75 | 1.80 | $628,228 | $176,819 |
| 2015 | 816 | 2,164 | 74 | 1.98 | $706,067 | $209,456 |
| 2014 | 794 | 2,360 | 75 | 1.72 | $643,949 | $250,232 |
| 2013 | 607 | 1,702 | 74 | 1.77 | $457,555 | $170,717 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 21 services
| Long return visit (40+ min) | 109 | $24,440 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 89 | $21,671 | $104 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 91 | $17,550 | $185 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 244 | $15,417 | $61 |
| Return visit (30+ min) | 76 | $9,613 | $108 |
| Critical care, first 30-74 minutes | 23 | $9,460 | $185 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $7,702 | $154 |
| New patient visit (60+ min) | 29 | $5,608 | $193 |
| Ultrasound of both sides of head and neck blood flow | 17 | $2,733 | $161 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 133 | $1,882 | $13 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 28 | $1,692 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,617 | $70 |
| Ultrasound of heart, follow-up | 54 | $1,259 | $22 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 63 | $1,212 | $19 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,037 | $94 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 63 | $795 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 54 | $357 | $6 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 12 | $271 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 12 | $190 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 56 | $162 | $3 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 12 | $155 | $12 |
2022: 21 services
| Long return visit (40+ min) | 121 | $30,392 | $155 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 137 | $27,210 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 114 | $26,215 | $90 |
| Critical care, first 30-74 minutes | 45 | $21,233 | $188 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 263 | $17,573 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $10,239 | $171 |
| Return visit (30+ min) | 60 | $6,869 | $100 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $2,683 | $224 |
| New patient visit (60+ min) | 14 | $2,440 | $174 |
| Ultrasound of both sides of head and neck blood flow | 13 | $2,178 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,080 | $63 |
| Ultrasound of heart, follow-up | 83 | $1,949 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 137 | $1,913 | $12 |
| Ultrasound of heart with probe in esophagus, with report | 18 | $1,830 | $96 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 83 | $553 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 22 | $406 | $18 |
| Ultrasound of heart blood flow, valves and chambers | 18 | $306 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 97 | $292 | $3 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 22 | $277 | $13 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 12 | $263 | $22 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 12 | $166 | $14 |
2021: 21 services
| Critical care, first 30-74 minutes | 57 | $26,856 | $193 |
| Long return visit (40+ min) | 113 | $25,134 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 110 | $24,839 | $92 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 106 | $21,335 | $198 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 300 | $19,720 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 73 | $14,139 | $179 |
| Return visit (30+ min) | 93 | $11,615 | $93 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 31 | $7,079 | $228 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $2,890 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 126 | $1,862 | $13 |
| Ultrasound of heart with probe in esophagus, with report | 18 | $1,857 | $98 |
| Ultrasound of heart, follow-up | 62 | $1,426 | $23 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,125 | $87 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 15 | $957 | $64 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 41 | $809 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 41 | $542 | $13 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 64 | $423 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 12 | $320 | $25 |
| Ultrasound of heart blood flow, valves and chambers | 18 | $311 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 81 | $237 | $3 |
| Heart rhythm recording of continous external ekg over 8-15 days | 12 | $201 | $15 |
2020: 24 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 116 | $23,769 | $200 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $19,749 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 275 | $19,450 | $68 |
| Critical care, first 30-74 minutes | 38 | $19,141 | $199 |
| Long return visit (40+ min) | 96 | $15,036 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $12,379 | $185 |
| Return visit (30+ min) | 103 | $10,043 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $4,361 | $66 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 16 | $3,592 | $224 |
| Ultrasound of both sides of head and neck blood flow | 16 | $2,616 | $164 |
| New patient visit (60+ min) | 12 | $1,814 | $151 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 20 | $1,389 | $66 |
| Ultrasound of heart, follow-up | 56 | $1,378 | $24 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,218 | $101 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,105 | $85 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 35 | $728 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 45 | $628 | $14 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $609 | $43 |
| External ekg recording for more than 48 hours up to 21 days | 19 | $529 | $28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 35 | $488 | $14 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 19 | $467 | $25 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 57 | $397 | $7 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $222 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 69 | $213 | $3 |
2019: 28 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 263 | $51,690 | $192 |
| Long return visit (40+ min) | 143 | $26,591 | $123 |
| Return visit (30+ min) | 188 | $23,177 | $92 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 317 | $21,560 | $66 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 37 | $15,367 | $415 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 73 | $14,758 | $91 |
| Critical care, first 30-74 minutes | 32 | $11,816 | $194 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,786 | $179 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 37 | $7,073 | $96 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 27 | $5,864 | $217 |
| New patient visit (60+ min) | 31 | $5,534 | $179 |
| Injection, regadenoson, 0.1 mg | 28 | $5,083 | None |
| Ultrasound of both sides of head and neck blood flow | 28 | $4,629 | $165 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,547 | $64 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 56 | $3,211 | $57 |
| Programming of dual lead implantable defibrillator system | 18 | $2,035 | $78 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 31 | $1,978 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 126 | $1,967 | $15 |
| New patient visit (45+ min) | 15 | $1,920 | $128 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,373 | $98 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 57 | $1,156 | $20 |
| Ultrasound of heart, follow-up | 40 | $1,017 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 57 | $775 | $13 |
| Electrocardiogram (ecg) 2-day continuous | 16 | $400 | $25 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 16 | $383 | $24 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 41 | $295 | $7 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $232 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 53 | $171 | $3 |
2018: 26 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 253 | $46,716 | $182 |
| Long return visit (40+ min) | 109 | $22,834 | $114 |
| Return visit (30+ min) | 162 | $22,183 | $82 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 48 | $19,132 | $399 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 147 | $9,336 | $61 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 48 | $8,534 | $89 |
| Critical care, first 30-74 minutes | 25 | $7,427 | $181 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 32 | $6,280 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $5,351 | $85 |
| Ultrasound of both sides of head and neck blood flow | 30 | $4,750 | $158 |
| Injection, regadenoson, 0.1 mg | 27 | $4,702 | None |
| New patient visit (60+ min) | 26 | $4,202 | $162 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 55 | $3,067 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,019 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,892 | $59 |
| New patient visit (45+ min) | 14 | $1,655 | $118 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 105 | $1,446 | $12 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,275 | $91 |
| Ultrasound of heart, follow-up | 32 | $709 | $21 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 20 | $384 | $19 |
| Electrocardiogram (ecg) 2-day continuous | 20 | $382 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 14 | $241 | $17 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $215 | $15 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 32 | $201 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 14 | $162 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 45 | $125 | $3 |
2017: 22 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 173 | $35,814 | $203 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 57 | $21,938 | $385 |
| Return visit (30+ min) | 151 | $21,595 | $84 |
| Long return visit (40+ min) | 103 | $21,110 | $117 |
| Critical care, first 30-74 minutes | 17 | $13,823 | $177 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 57 | $9,997 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $8,420 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 127 | $6,938 | $53 |
| Injection, regadenoson, 0.1 mg | 33 | $5,597 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 20 | $4,896 | $245 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,808 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $4,301 | $59 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 63 | $3,691 | $59 |
| Ultrasound of both sides of head and neck blood flow | 23 | $3,151 | $121 |
| New patient visit (60+ min) | 13 | $2,015 | $155 |
| New patient visit (45+ min) | 14 | $1,550 | $111 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 74 | $1,106 | $13 |
| Ultrasound of heart, follow-up | 28 | $593 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 15 | $274 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 15 | $184 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 28 | $168 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 35 | $92 | $3 |
2016: 25 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 174 | $35,833 | $205 |
| Long return visit (40+ min) | 136 | $27,525 | $117 |
| Return visit (30+ min) | 180 | $25,463 | $84 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 50 | $19,239 | $385 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 50 | $9,250 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 149 | $8,070 | $54 |
| Critical care, first 30-74 minutes | 19 | $5,977 | $181 |
| New patient visit (60+ min) | 31 | $4,690 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $4,683 | $85 |
| Injection, regadenoson, 0.1 mg | 25 | $4,227 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 16 | $4,037 | $252 |
| Ultrasound of both sides of head and neck blood flow | 27 | $3,600 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,585 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,578 | $170 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 57 | $3,363 | $59 |
| New patient visit (45+ min) | 17 | $2,091 | $123 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 89 | $1,375 | $13 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,340 | $103 |
| Programming of dual lead implantable defibrillator system | 13 | $1,115 | $62 |
| Electrocardiogram (ecg) 2-day continuous | 39 | $941 | $24 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 39 | $841 | $22 |
| Ultrasound of heart, follow-up | 22 | $483 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 15 | $236 | $16 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 22 | $137 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 37 | $101 | $3 |
2015: 26 services
| Long return visit (40+ min) | 162 | $34,723 | $113 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 167 | $33,884 | $202 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 73 | $28,487 | $390 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 73 | $19,060 | $131 |
| Return visit (30+ min) | 141 | $18,975 | $83 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 196 | $10,658 | $54 |
| Injection, regadenoson, 0.1 mg | 49 | $8,149 | None |
| Critical care, first 30-74 minutes | 18 | $7,043 | $185 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,339 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $5,724 | $60 |
| New patient visit (60+ min) | 34 | $5,456 | $160 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 82 | $4,928 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $4,787 | $85 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 14 | $3,525 | $252 |
| Programming of dual lead implantable defibrillator system | 24 | $2,034 | $68 |
| Ultrasound of both sides of head and neck blood flow | 14 | $2,020 | $135 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 113 | $1,795 | $14 |
| New patient visit (45+ min) | 11 | $1,333 | $121 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,130 | $103 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 15 | $1,036 | $69 |
| Ultrasound of heart, follow-up | 37 | $831 | $22 |
| Electrocardiogram (ecg) 2-day continuous | 24 | $599 | $25 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 25 | $574 | $23 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 37 | $236 | $6 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $204 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 50 | $145 | $3 |
2014: 26 services
| Long return visit (40+ min) | 176 | $42,579 | $121 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 195 | $39,742 | $204 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 88 | $35,351 | $393 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 88 | $20,933 | $118 |
| Return visit (30+ min) | 125 | $16,291 | $88 |
| Critical care, first 30-74 minutes | 32 | $15,977 | $188 |
| Injection, regadenoson, 0.1 mg | 62 | $10,466 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 167 | $9,378 | $55 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 31 | $7,959 | $257 |
| New patient visit (60+ min) | 41 | $6,944 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $5,818 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 91 | $5,663 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,751 | $170 |
| New patient visit (45+ min) | 31 | $4,349 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $4,107 | $89 |
| Ultrasound of both sides of head and neck blood flow | 19 | $2,848 | $142 |
| Programming of multiple lead implantable defibrillator system | 19 | $2,712 | $80 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 119 | $1,857 | $14 |
| Programming of dual lead implantable defibrillator system | 14 | $1,759 | $70 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,412 | $118 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 17 | $1,263 | $74 |
| Ultrasound of heart, follow-up | 31 | $802 | $22 |
| Electrocardiogram (ecg) 2-day continuous | 24 | $604 | $25 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 24 | $561 | $23 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 31 | $229 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 38 | $128 | $3 |
2013: 20 services
| Long return visit (40+ min) | 124 | $32,318 | $121 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 62 | $25,256 | $401 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 139 | $22,912 | $165 |
| Return visit (30+ min) | 96 | $14,558 | $86 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 62 | $14,481 | $117 |
| Critical care, first 30-74 minutes | 18 | $6,653 | $185 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 123 | $6,636 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $6,333 | $60 |
| Injection, regadenoson, 0.1 mg | 33 | $5,445 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 23 | $4,717 | $205 |
| New patient visit (60+ min) | 25 | $4,331 | $173 |
| New patient visit (45+ min) | 32 | $4,124 | $129 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 65 | $4,109 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,052 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,162 | $86 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 94 | $1,782 | $17 |
| Electrocardiogram (ecg) 2-day continuous | 42 | $1,073 | $26 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 42 | $918 | $22 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 11 | $791 | $72 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 15 | $47 | $3 |
Medicaid work
$3,710 in 2024
Medicaid paid $3,710 for 156 billed services this clinician did in 2024, up to 28 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 144 | $3,668 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 12 | $42 |
| 2024 | 156 | 2 | 28 | $3,710 |
| 2023 | 296 | 3 | 35 | $6,839 |
| 2022 | 309 | 1 | 42 | $7,330 |
| 2021 | 346 | 5 | 32 | $7,839 |
| 2020 | 228 | 2 | 29 | $5,445 |
| 2019 | 341 | 2 | 43 | $9,690 |
| 2018 | 280 | 3 | 36 | $5,717 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 255 | $6,713 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 29 | $114 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 12 | $12 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 309 | $7,330 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 260 | $6,948 |
| Long return visit (40+ min) | 13 | $669 |
| ECHO TRANSTHORC R-T 2D W/WO M-MODE REC F-UP/LMTD | 24 | $144 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 24 | $61 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 25 | $16 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 212 | $5,064 |
| Return visit (30+ min) | 16 | $381 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 327 | $9,505 |
| Return visit (30+ min) | 14 | $185 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 243 | $5,198 |
| Return visit (30+ min) | 25 | $469 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 12 | $50 |
Drugs they prescribed that Part D paid
$1,400,661
Pharmacies billed $1,400,661 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,525) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,893 generic and 632 brand-name prescriptions · $1,400,661 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Uptravi | 24 | $524,434 | $21,851 |
| Eliquis | 262 | $312,964 | $1,195 |
| Entresto | 131 | $142,714 | $1,089 |
| Opsumit | 12 | $135,552 | $11,296 |
| Farxiga | 75 | $70,637 | $942 |
See all 43 drugs
| Uptravi | 24 | $524,434 | $21,851 |
| Eliquis | 262 | $312,964 | $1,195 |
| Entresto | 131 | $142,714 | $1,089 |
| Opsumit | 12 | $135,552 | $11,296 |
| Farxiga | 75 | $70,637 | $942 |
| Multaq | 24 | $43,349 | $1,806 |
| Xarelto | 21 | $26,010 | $1,239 |
| Ambrisentan | 13 | $23,883 | $1,837 |
| Jardiance | 15 | $16,411 | $1,094 |
| Nebivolol | 63 | $5,063 | $80 |
| Metoprolol | 312 | $4,534 | $15 |
| Ezetimibe | 81 | $4,404 | $54 |
| Vascepa | 11 | $3,799 | $345 |
| Atorvastatin | 285 | $2,965 | $10 |
| Bumetanide | 51 | $1,819 | $36 |
| Olmesartan-Hydrochlorothiazide | 12 | $873 | $73 |
| Potassium Chloride | 36 | $853 | $24 |
| Digoxin | 36 | $830 | $23 |
| Carvedilol | 80 | $778 | $10 |
| Rosuvastatin | 55 | $767 | $14 |
| Furosemide | 88 | $679 | $8 |
| Lisinopril | 86 | $666 | $8 |
| Losartan | 91 | $649 | $7 |
| Amlodipine Besylate | 81 | $578 | $7 |
| Escitalopram | 31 | $544 | $18 |
| Clopidogrel | 36 | $402 | $11 |
| Tadalafil | 13 | $395 | $30 |
| Olmesartan Medoxomil | 20 | $384 | $19 |
| Isosorbide Mononitrate Er | 25 | $372 | $15 |
| Pantoprazole | 11 | $305 | $28 |
| Levothyroxine | 18 | $286 | $16 |
| Hydrochlorothiazide | 25 | $269 | $11 |
| Spironolactone | 54 | $267 | $5 |
| Chlorthalidone | 14 | $252 | $18 |
| Simvastatin | 23 | $226 | $10 |
| Losartan-Hydrochlorothiazide | 15 | $222 | $15 |
| Metoprolol | 27 | $188 | $7 |
| Omeprazole | 12 | $188 | $16 |
| Ramipril | 12 | $164 | $14 |
| Nitroglycerin | 11 | $159 | $14 |
| Hydralazine | 17 | $123 | $7 |
| Famotidine | 16 | $93 | $6 |
| Amoxicillin | 12 | $13 | $1 |
Year by year
| 2024 | 2,525 | 361 | 0% (0) | 25% | $1,400,661 |
| 2023 | 2,393 | 347 | 0% (0) | None | $1,449,601 |
| 2022 | 2,278 | 325 | 0% (0) | None | $1,163,724 |
| 2021 | 2,164 | 343 | 0% (0) | 21% | $1,101,996 |
| 2020 | 2,461 | 376 | 0% (0) | 23% | $1,040,894 |
| 2019 | 1,911 | 358 | None | 21% | $836,571 |
| 2018 | 1,652 | 292 | None | 24% | $964,584 |
| 2017 | 1,583 | 232 | 0% (0) | 37% | $1,271,488 |
| 2016 | 1,842 | 240 | 0% (0) | 35% | $759,170 |
| 2015 | 2,143 | 260 | None | 35% | $317,854 |
| 2014 | 2,277 | 273 | None | 36% | $426,937 |
| 2013 | 2,408 | 260 | None | None | $423,940 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 38 drugs
| Uptravi | 24 | $560,204 | $23,342 |
| Eliquis | 241 | $269,634 | $1,119 |
| Opsumit | 13 | $170,131 | $13,087 |
| Entresto | 143 | $165,494 | $1,157 |
| Xarelto | 38 | $48,908 | $1,287 |
| Farxiga | 35 | $35,939 | $1,027 |
| Multaq | 13 | $21,546 | $1,657 |
| Nebivolol | 108 | $8,938 | $83 |
| Metoprolol | 283 | $5,241 | $19 |
| Atorvastatin | 245 | $4,232 | $17 |
| Ezetimibe | 61 | $3,064 | $50 |
| Bumetanide | 46 | $1,704 | $37 |
| Potassium Chloride | 32 | $1,597 | $50 |
| Losartan | 78 | $1,434 | $18 |
| Carvedilol | 93 | $1,380 | $15 |
| Digoxin | 33 | $1,206 | $37 |
| Isosorbide Dinitrate | 19 | $1,203 | $63 |
| Rosuvastatin | 44 | $1,185 | $27 |
| Amlodipine Besylate | 94 | $954 | $10 |
| Valsartan | 12 | $888 | $74 |
| Lisinopril | 87 | $865 | $10 |
| Escitalopram | 26 | $783 | $30 |
| Torsemide | 11 | $723 | $66 |
| Furosemide | 83 | $691 | $8 |
| Isosorbide Mononitrate Er | 16 | $650 | $41 |
| Clopidogrel | 36 | $604 | $17 |
| Losartan-Hydrochlorothiazide | 19 | $513 | $27 |
| Levothyroxine | 19 | $474 | $25 |
| Hydralazine | 28 | $431 | $15 |
| Spironolactone | 47 | $423 | $9 |
| Olmesartan Medoxomil | 14 | $338 | $24 |
| Hydrochlorothiazide | 31 | $264 | $9 |
| Ramipril | 14 | $218 | $16 |
| Pantoprazole | 11 | $214 | $19 |
| Metoprolol | 21 | $179 | $9 |
| Famotidine | 24 | $150 | $6 |
| Simvastatin | 15 | $120 | $8 |
| Amoxicillin | 15 | $29 | $2 |
2022: 36 drugs
| Uptravi | 22 | $451,363 | $20,516 |
| Eliquis | 190 | $199,646 | $1,051 |
| Opsumit | 12 | $143,547 | $11,962 |
| Entresto | 127 | $125,668 | $990 |
| Xarelto | 33 | $41,342 | $1,253 |
| Farxiga | 16 | $13,846 | $865 |
| Jardiance | 11 | $7,020 | $638 |
| Bystolic | 12 | $6,901 | $575 |
| Nebivolol | 71 | $5,856 | $82 |
| Metoprolol | 296 | $5,094 | $17 |
| Atorvastatin | 215 | $3,732 | $17 |
| Ezetimibe | 50 | $3,287 | $66 |
| Potassium Chloride | 49 | $2,302 | $47 |
| Bumetanide | 36 | $1,739 | $48 |
| Digoxin | 38 | $1,369 | $36 |
| Carvedilol | 86 | $1,253 | $15 |
| Isosorbide Dinitrate | 19 | $1,155 | $61 |
| Amlodipine Besylate | 105 | $870 | $8 |
| Lisinopril | 111 | $825 | $7 |
| Losartan | 68 | $694 | $10 |
| Clopidogrel | 28 | $691 | $25 |
| Amiodarone | 28 | $680 | $24 |
| Losartan-Hydrochlorothiazide | 40 | $615 | $15 |
| Isosorbide Mononitrate Er | 13 | $595 | $46 |
| Hydralazine | 35 | $586 | $17 |
| Rosuvastatin | 24 | $576 | $24 |
| Hydrochlorothiazide | 40 | $441 | $11 |
| Spironolactone | 41 | $430 | $10 |
| Furosemide | 78 | $411 | $5 |
| Escitalopram | 21 | $302 | $14 |
| Pravastatin | 11 | $256 | $23 |
| Olmesartan Medoxomil | 16 | $221 | $14 |
| Metoprolol | 33 | $185 | $6 |
| Famotidine | 16 | $160 | $10 |
| Ramipril | 13 | $124 | $10 |
| Simvastatin | 23 | $108 | $5 |
2021: 37 drugs
| Uptravi | 23 | $452,878 | $19,690 |
| Eliquis | 186 | $207,245 | $1,114 |
| Opsumit | 14 | $150,470 | $10,748 |
| Entresto | 72 | $67,888 | $943 |
| Ambrisentan | 11 | $67,286 | $6,117 |
| Xarelto | 36 | $41,235 | $1,145 |
| Bystolic | 45 | $18,934 | $421 |
| Metoprolol | 344 | $6,811 | $20 |
| Ezetimibe | 61 | $4,139 | $68 |
| Atorvastatin | 229 | $3,568 | $16 |
| Ranolazine Er | 17 | $3,091 | $182 |
| Potassium Chloride | 27 | $1,331 | $49 |
| Valsartan | 14 | $1,199 | $86 |
| Bumetanide | 19 | $968 | $51 |
| Diltiazem 24hr Er (Cd) | 19 | $942 | $50 |
| Lisinopril | 131 | $936 | $7 |
| Carvedilol | 69 | $930 | $13 |
| Olmesartan Medoxomil | 31 | $795 | $26 |
| Losartan-Hydrochlorothiazide | 45 | $727 | $16 |
| Losartan | 60 | $695 | $12 |
| Digoxin | 19 | $649 | $34 |
| Amlodipine Besylate | 75 | $609 | $8 |
| Rosuvastatin | 24 | $594 | $25 |
| Clopidogrel | 26 | $553 | $21 |
| Escitalopram | 27 | $533 | $20 |
| Prasugrel | 12 | $522 | $44 |
| Hydrochlorothiazide | 58 | $415 | $7 |
| Furosemide | 66 | $389 | $6 |
| Isosorbide Mononitrate Er | 16 | $379 | $24 |
| Amiodarone | 18 | $377 | $21 |
| Metoprolol | 41 | $374 | $9 |
| Hydralazine | 18 | $358 | $20 |
| Spironolactone | 36 | $357 | $10 |
| Levothyroxine | 16 | $312 | $19 |
| Pravastatin | 18 | $300 | $17 |
| Ramipril | 16 | $239 | $15 |
| Simvastatin | 29 | $113 | $4 |
2020: 39 drugs
| Uptravi | 23 | $412,313 | $17,927 |
| Eliquis | 204 | $178,666 | $876 |
| Opsumit | 12 | $123,471 | $10,289 |
| Ambrisentan | 13 | $64,533 | $4,964 |
| Xarelto | 40 | $42,488 | $1,062 |
| Entresto | 42 | $41,274 | $983 |
| Tadalafil | 13 | $34,049 | $2,619 |
| Bystolic | 75 | $24,733 | $330 |
| Praluent | 18 | $16,874 | $937 |
| Propafenone Hcl Er | 19 | $14,836 | $781 |
| Metoprolol | 315 | $9,781 | $31 |
| Vascepa | 20 | $7,095 | $355 |
| Ezetimibe | 57 | $3,899 | $68 |
| Atorvastatin | 229 | $3,886 | $17 |
| Prasugrel | 14 | $2,760 | $197 |
| Diltiazem 24hr Er (Cd) | 26 | $2,485 | $96 |
| Potassium Chloride | 45 | $2,340 | $52 |
| Olmesartan Medoxomil | 54 | $2,231 | $41 |
| Valsartan | 19 | $2,151 | $113 |
| Carvedilol | 123 | $1,940 | $16 |
| Digoxin | 36 | $1,639 | $46 |
| Bumetanide | 27 | $1,340 | $50 |
| Ranolazine Er | 11 | $1,308 | $119 |
| Isosorbide Mononitrate Er | 40 | $1,164 | $29 |
| Losartan | 98 | $996 | $10 |
| Rosuvastatin | 13 | $936 | $72 |
| Lisinopril | 104 | $818 | $8 |
| Losartan-Hydrochlorothiazide | 32 | $725 | $23 |
| Amlodipine Besylate | 93 | $612 | $7 |
| Furosemide | 93 | $590 | $6 |
| Hydrochlorothiazide | 78 | $574 | $7 |
| Escitalopram | 28 | $562 | $20 |
| Nitroglycerin | 12 | $513 | $43 |
| Warfarin | 20 | $513 | $26 |
| Ramipril | 43 | $511 | $12 |
| Spironolactone | 50 | $405 | $8 |
| Clopidogrel | 21 | $327 | $16 |
| Simvastatin | 45 | $314 | $7 |
| Metoprolol | 37 | $228 | $6 |
2019: 39 drugs
| Uptravi | 18 | $302,028 | $16,779 |
| Eliquis | 165 | $130,264 | $789 |
| Opsumit | 12 | $123,946 | $10,329 |
| Tadalafil | 25 | $40,663 | $1,627 |
| Xarelto | 23 | $27,835 | $1,210 |
| Entresto | 26 | $20,806 | $800 |
| Bystolic | 40 | $15,056 | $376 |
| Propafenone Hcl Er | 15 | $12,507 | $834 |
| Metoprolol | 264 | $7,543 | $29 |
| Ezetimibe | 45 | $3,439 | $76 |
| Prasugrel | 19 | $3,235 | $170 |
| Bumetanide | 20 | $3,230 | $162 |
| Atorvastatin | 139 | $2,673 | $19 |
| Carvedilol Er | 12 | $2,507 | $209 |
| Olmesartan Medoxomil | 27 | $1,669 | $62 |
| Isosorbide Mononitrate Er | 42 | $1,183 | $28 |
| Potassium Chloride | 45 | $1,166 | $26 |
| Rosuvastatin | 12 | $1,143 | $95 |
| Amlodipine Besylate | 99 | $1,142 | $12 |
| Digoxin | 21 | $1,078 | $51 |
| Diltiazem 24hr Er (Cd) | 13 | $1,070 | $82 |
| Carvedilol | 91 | $915 | $10 |
| Olmesartan-Hydrochlorothiazide | 19 | $898 | $47 |
| Warfarin | 30 | $806 | $27 |
| Losartan-Hydrochlorothiazide | 57 | $727 | $13 |
| Lisinopril | 80 | $668 | $8 |
| Spironolactone | 45 | $503 | $11 |
| Losartan | 51 | $470 | $9 |
| Nitroglycerin | 20 | $464 | $23 |
| Digox | 11 | $449 | $41 |
| Ramipril | 19 | $392 | $21 |
| Clopidogrel | 24 | $379 | $16 |
| Escitalopram | 19 | $363 | $19 |
| Chlorthalidone | 11 | $344 | $31 |
| Hydrochlorothiazide | 26 | $325 | $12 |
| Simvastatin | 27 | $298 | $11 |
| Metoprolol | 40 | $292 | $7 |
| Furosemide | 57 | $283 | $5 |
| Pantoprazole | 13 | $146 | $11 |
2018: 40 drugs
| Uptravi | 21 | $369,140 | $17,578 |
| Opsumit | 16 | $149,241 | $9,328 |
| Letairis | 14 | $133,923 | $9,566 |
| Adcirca | 20 | $82,498 | $4,125 |
| Eliquis | 74 | $58,233 | $787 |
| Xarelto | 44 | $32,405 | $736 |
| Entresto | 26 | $19,534 | $751 |
| Multaq | 16 | $17,587 | $1,099 |
| Propafenone Hcl Er | 19 | $11,847 | $624 |
| Bystolic | 32 | $8,676 | $271 |
| Ezetimibe | 41 | $6,224 | $152 |
| Metoprolol | 195 | $5,718 | $29 |
| Prasugrel | 16 | $3,823 | $239 |
| Atorvastatin | 128 | $2,686 | $21 |
| Carvedilol Er | 12 | $2,682 | $223 |
| Olmesartan-Hydrochlorothiazide | 37 | $1,704 | $46 |
| Olmesartan Medoxomil | 27 | $1,372 | $51 |
| Rosuvastatin | 16 | $1,121 | $70 |
| Isosorbide Mononitrate Er | 53 | $976 | $18 |
| Digoxin | 15 | $942 | $63 |
| Chlorthalidone | 23 | $829 | $36 |
| Valsartan | 33 | $777 | $24 |
| Propafenone | 12 | $774 | $65 |
| Escitalopram | 36 | $634 | $18 |
| Nitroglycerin | 23 | $579 | $25 |
| Carvedilol | 50 | $446 | $9 |
| Amlodipine Besylate | 44 | $433 | $10 |
| Potassium Chloride | 17 | $430 | $25 |
| Warfarin | 21 | $418 | $20 |
| Clopidogrel | 49 | $392 | $8 |
| Losartan-Hydrochlorothiazide | 34 | $387 | $11 |
| Lisinopril | 58 | $329 | $6 |
| Amiodarone | 17 | $296 | $17 |
| Losartan | 33 | $278 | $8 |
| Metoprolol | 44 | $249 | $6 |
| Simvastatin | 19 | $229 | $12 |
| Hydrochlorothiazide | 32 | $223 | $7 |
| Spironolactone | 16 | $169 | $11 |
| Furosemide | 51 | $160 | $3 |
| Sertraline | 25 | $137 | $5 |
2017: 37 drugs
| Uptravi | 34 | $567,184 | $16,682 |
| Opsumit | 25 | $218,310 | $8,732 |
| Letairis | 16 | $148,216 | $9,264 |
| Adcirca | 32 | $114,168 | $3,568 |
| Eliquis | 79 | $54,039 | $684 |
| Xarelto | 55 | $35,236 | $641 |
| Multaq | 23 | $17,919 | $779 |
| Propafenone Hcl Er | 29 | $15,506 | $535 |
| Bystolic | 36 | $10,021 | $278 |
| Entresto | 11 | $8,195 | $745 |
| Olmesartan-Hydrochlorothiazide | 21 | $5,248 | $250 |
| Olmesartan Medoxomil | 19 | $4,696 | $247 |
| Metoprolol | 170 | $4,662 | $27 |
| Ezetimibe | 13 | $3,585 | $276 |
| Atorvastatin | 108 | $2,104 | $19 |
| Digoxin | 19 | $1,444 | $76 |
| Bumetanide | 18 | $1,017 | $56 |
| Amlodipine-Olmesartan | 11 | $993 | $90 |
| Rosuvastatin | 16 | $895 | $56 |
| Valsartan | 29 | $759 | $26 |
| Digox | 12 | $735 | $61 |
| Carvedilol | 63 | $691 | $11 |
| Propafenone | 11 | $635 | $58 |
| Isosorbide Mononitrate Er | 38 | $525 | $14 |
| Escitalopram | 46 | $448 | $10 |
| Lisinopril | 75 | $386 | $5 |
| Potassium Chloride | 17 | $356 | $21 |
| Spironolactone | 37 | $344 | $9 |
| Losartan-Hydrochlorothiazide | 33 | $306 | $9 |
| Warfarin | 17 | $280 | $16 |
| Furosemide | 57 | $217 | $4 |
| Amlodipine Besylate | 32 | $217 | $7 |
| Clopidogrel | 17 | $206 | $12 |
| Metoprolol | 32 | $185 | $6 |
| Sertraline | 28 | $162 | $6 |
| Losartan | 30 | $127 | $4 |
| Hydrochlorothiazide | 11 | $86 | $8 |
2016: 43 drugs
| Uptravi | 16 | $319,345 | $19,959 |
| Opsumit | 14 | $109,220 | $7,801 |
| Adcirca | 18 | $52,591 | $2,922 |
| Eliquis | 70 | $28,513 | $407 |
| Xarelto | 41 | $25,263 | $616 |
| Pradaxa | 28 | $12,876 | $460 |
| Ranexa | 15 | $11,064 | $738 |
| Multaq | 19 | $10,394 | $547 |
| Benicar | 36 | $10,031 | $279 |
| Bystolic | 44 | $9,403 | $214 |
| Propafenone Hcl Er | 26 | $9,022 | $347 |
| Effient | 13 | $8,948 | $688 |
| Benicar Hct | 23 | $6,944 | $302 |
| Coreg Cr | 11 | $6,783 | $617 |
| Metoprolol | 222 | $5,051 | $23 |
| Lexapro | 17 | $4,266 | $251 |
| Crestor | 15 | $3,069 | $205 |
| Livalo | 14 | $3,012 | $215 |
| Lipitor | 13 | $2,913 | $224 |
| Atorvastatin | 97 | $1,668 | $17 |
| Bumetanide | 36 | $979 | $27 |
| Digoxin | 30 | $977 | $33 |
| Carvedilol | 94 | $889 | $9 |
| Valsartan | 31 | $851 | $27 |
| Lisinopril | 126 | $812 | $6 |
| Escitalopram | 44 | $643 | $15 |
| Digox | 14 | $618 | $44 |
| Warfarin | 31 | $594 | $19 |
| Diltiazem 24hr Er | 23 | $548 | $24 |
| Losartan | 64 | $471 | $7 |
| Potassium Chloride | 29 | $461 | $16 |
| Amlodipine Besylate | 72 | $432 | $6 |
| Spironolactone | 49 | $409 | $8 |
| Losartan-Hydrochlorothiazide | 52 | $400 | $8 |
| Metoprolol | 50 | $247 | $5 |
| Ramipril | 13 | $228 | $18 |
| Clopidogrel | 12 | $213 | $18 |
| Hydrochlorothiazide | 19 | $195 | $10 |
| Pantoprazole | 19 | $182 | $10 |
| Simvastatin | 14 | $181 | $13 |
| Furosemide | 38 | $134 | $4 |
| Sertraline | 19 | $124 | $7 |
| Hydralazine | 13 | $104 | $8 |
2015: 42 drugs
| Letairis | 11 | $84,858 | $7,714 |
| Xarelto | 71 | $32,136 | $453 |
| Eliquis | 85 | $29,384 | $346 |
| Ranexa | 30 | $15,522 | $517 |
| Pradaxa | 31 | $13,537 | $437 |
| Multaq | 21 | $9,759 | $465 |
| Propafenone Hcl Er | 26 | $9,267 | $356 |
| Benicar | 40 | $8,863 | $222 |
| Coreg Cr | 20 | $7,297 | $365 |
| Metoprolol | 238 | $6,612 | $28 |
| Bystolic | 42 | $6,392 | $152 |
| Crestor | 37 | $5,667 | $153 |
| Benicar Hct | 12 | $4,225 | $352 |
| Effient | 11 | $3,603 | $328 |
| Valsartan | 57 | $3,291 | $58 |
| Livalo | 15 | $2,799 | $187 |
| Atorvastatin | 113 | $1,958 | $17 |
| Digox | 40 | $1,731 | $43 |
| Digoxin | 31 | $1,003 | $32 |
| Potassium Chloride | 46 | $938 | $20 |
| Bumetanide | 30 | $843 | $28 |
| Carvedilol | 100 | $785 | $8 |
| Warfarin | 25 | $720 | $29 |
| Lisinopril | 167 | $714 | $4 |
| Diltiazem 24hr Er | 30 | $527 | $18 |
| Losartan-Hydrochlorothiazide | 53 | $436 | $8 |
| Amlodipine Besylate | 77 | $430 | $6 |
| Losartan | 57 | $411 | $7 |
| Amiodarone | 23 | $399 | $17 |
| Isosorbide Mononitrate Er | 19 | $371 | $20 |
| Irbesartan | 14 | $306 | $22 |
| Simvastatin | 43 | $279 | $6 |
| Ramipril | 16 | $264 | $17 |
| Clopidogrel | 19 | $260 | $14 |
| Spironolactone | 52 | $259 | $5 |
| Metoprolol | 68 | $257 | $4 |
| Furosemide | 54 | $185 | $3 |
| Pantoprazole | 14 | $182 | $13 |
| Hydrochlorothiazide | 23 | $161 | $7 |
| Sertraline | 22 | $145 | $7 |
| Escitalopram | 16 | $107 | $7 |
| Famotidine | 14 | $66 | $5 |
2014: 46 drugs
| Letairis | 14 | $101,037 | $7,217 |
| Opsumit | 13 | $90,718 | $6,978 |
| Xarelto | 111 | $41,580 | $375 |
| Eliquis | 59 | $17,059 | $289 |
| Pradaxa | 39 | $14,277 | $366 |
| Sildenafil | 12 | $11,053 | $921 |
| Benicar | 62 | $10,880 | $175 |
| Propafenone Hcl Er | 32 | $10,511 | $328 |
| Diovan | 41 | $9,026 | $220 |
| Metoprolol | 271 | $8,970 | $33 |
| Benicar Hct | 13 | $5,598 | $431 |
| Ranexa | 20 | $5,537 | $277 |
| Multaq | 11 | $4,432 | $403 |
| Bystolic | 42 | $4,419 | $105 |
| Coreg Cr | 15 | $4,189 | $279 |
| Atorvastatin | 155 | $2,501 | $16 |
| Digox | 62 | $1,932 | $31 |
| Digoxin | 48 | $1,922 | $40 |
| Carvedilol | 104 | $1,137 | $11 |
| Lisinopril | 175 | $942 | $5 |
| Potassium Chloride | 28 | $840 | $30 |
| Klor-Con 10 | 24 | $674 | $28 |
| Losartan | 42 | $542 | $13 |
| Levothyroxine | 37 | $526 | $14 |
| Hydrochlorothiazide | 67 | $524 | $8 |
| Amiodarone | 17 | $491 | $29 |
| Isosorbide Mononitrate Er | 26 | $425 | $16 |
| Bumetanide | 29 | $395 | $14 |
| Bisoprolol | 16 | $374 | $23 |
| Simvastatin | 45 | $370 | $8 |
| Diltiazem Er | 12 | $354 | $29 |
| Diltiazem 24hr Er | 20 | $333 | $17 |
| Warfarin | 18 | $329 | $18 |
| Amlodipine Besylate | 37 | $316 | $9 |
| Losartan-Hydrochlorothiazide | 30 | $315 | $10 |
| Torsemide | 12 | $315 | $26 |
| Escitalopram | 30 | $314 | $10 |
| Clopidogrel | 21 | $306 | $15 |
| Metoprolol | 66 | $293 | $4 |
| Ramipril | 16 | $287 | $18 |
| Spironolactone | 48 | $286 | $6 |
| Furosemide | 75 | $260 | $3 |
| Omeprazole | 16 | $131 | $8 |
| Sertraline | 14 | $106 | $8 |
| Famotidine | 12 | $72 | $6 |
| Clonidine | 12 | $54 | $5 |
2013: 41 drugs
| Letairis | 24 | $159,044 | $6,627 |
| Tracleer | 11 | $74,874 | $6,807 |
| Xarelto | 88 | $27,038 | $307 |
| Pradaxa | 54 | $18,157 | $336 |
| Diovan | 74 | $13,043 | $176 |
| Metoprolol | 234 | $8,597 | $37 |
| Propafenone | 38 | $8,535 | $225 |
| Multaq | 22 | $8,263 | $376 |
| Benicar | 47 | $7,640 | $163 |
| Bystolic | 50 | $5,952 | $119 |
| Ranexa | 22 | $5,823 | $265 |
| Eliquis | 20 | $5,077 | $254 |
| Benicar Hct | 18 | $4,945 | $275 |
| Livalo | 22 | $4,855 | $221 |
| Atorvastatin | 182 | $4,779 | $26 |
| Coreg Cr | 14 | $3,108 | $222 |
| Lovaza | 15 | $2,979 | $199 |
| Effient | 12 | $2,725 | $227 |
| Carvedilol | 137 | $1,934 | $14 |
| Clopidogrel | 25 | $1,479 | $59 |
| Potassium Chloride | 48 | $1,363 | $28 |
| Lisinopril | 187 | $1,098 | $6 |
| Digox | 107 | $1,026 | $10 |
| Klor-Con 10 | 33 | $865 | $26 |
| Warfarin | 38 | $747 | $20 |
| Losartan | 55 | $745 | $14 |
| Amlodipine Besylate | 74 | $728 | $10 |
| Torsemide | 19 | $618 | $33 |
| Ramipril | 43 | $610 | $14 |
| Propranolol | 14 | $493 | $35 |
| Simvastatin | 53 | $425 | $8 |
| Furosemide | 87 | $412 | $5 |
| Levothyroxine | 41 | $410 | $10 |
| Bumetanide | 38 | $395 | $10 |
| Hydrochlorothiazide | 52 | $365 | $7 |
| Metoprolol | 53 | $341 | $6 |
| Spironolactone | 24 | $231 | $10 |
| Amiodarone | 16 | $218 | $14 |
| Isosorbide Mononitrate Er | 17 | $182 | $11 |
| Digoxin | 19 | $180 | $9 |
| Nitrostat | 12 | $155 | $13 |
Money from drug and device companies
$62 in 2025
| 2025 | 2 | 3 | None | $62 |
| 2024 | 7 | 10 | None | $238 |
| 2023 | 7 | 10 | None | $615 |
| 2022 | 5 | 12 | None | $727 |
| 2021 | 6 | 16 | None | $612 |
| 2020 | 7 | 19 | None | $1,442 |
| 2019 | 21 | 88 | None | $1,874 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Winrevair | $34 | 2 payments
|
| Boston Scientific | General - Therapies | $28 | 1 payment
|
See all 3 published payments
| Merck Sharp & Dohme | Meals · 2025-11-13 | Winrevair | $18 |
| Boston Scientific | Meals · 2025-07-24 | General - Therapies | $28 |
| Merck Sharp & Dohme | Meals · 2025-01-28 | None | $16 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $238
| Novartis Pharmaceuticals | Leqvio | $104 | 4 payments
|
| Medtronic | Cobalt Dr Mri Surescan | $30 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $27 | 1 payment
|
| Merck Sharp & Dohme | Winrevair | $24 | 1 payment
|
| Abbott Laboratories | Assurity | $23 | 1 payment
|
| Esperion Therapeutics | Nexletol | $15 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $15 | 1 payment
|
2023: $615
| Medtronic | Advisa Dr Mri Surescan | $262 | 3 payments
|
| Edwards Lifesciences | Sapien 3 Ultra Resilia | $106 | 1 payment
|
| Impulse Dynamics (USA) | Optimizer | $99 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $75 | 1 payment
|
| Boston Scientific | Lux-Dx Insertable Cardiac Monitor | $32 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $22 | 1 payment
|
| Scpharmaceuticals | Furoscix | $18 | 1 payment
|
2022: $727
| Medtronic | Azure Xt Dr Mri Surescan | $541 | 7 payments
|
| Abbott Laboratories | Mitraclip | $97 | 1 payment
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $55 | 2 payments
|
| Pfizer | Vyndaqel | $22 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $12 | 1 payment
|
2021: $612
| Medtronic | Azure | $425 | 7 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $81 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $45 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $36 | 1 payment
|
| Esperion Therapeutics | Nexletol | $13 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $12 | 1 payment
|
2020: $1,442
| Abbott Laboratories | Mitra Clip System | $1,342 | 13 payments
|
| Medtronic Vascular | Cobalt | $27 | 1 payment
|
| iRhythm Technologies | Zio Patch | $25 | 1 payment
|
| Pfizer | Eliquis | $17 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $14 | 1 payment
|
| Esperion Therapeutics | Nexletol | $13 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $4 | 1 payment
|
2019: $1,874
| Medtronic Vascular | Azure | $236 | 5 payments
|
| Akcea Therapeutics | Tegsedi | $175 | 4 payments
|
| Actelion Pharmaceuticals US | Opsumit | $163 | 9 payments
|
| Novartis Pharmaceuticals | Entresto | $155 | 10 payments
|
| Janssen Pharmaceuticals | Xarelto | $141 | 8 payments
|
| Abbott Laboratories | Cardiomems Hf System | $120 | 4 payments
|
| Amgen | Repatha | $120 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $116 | 11 payments
|
| Regeneron Healthcare Solutions | Praluent | $91 | 5 payments
|
| Sanofi-Aventis U.S. | Praluent | $89 | 5 payments
|
| Pfizer | Chantix | $71 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $71 | 3 payments
|
| United Therapeutics | Orenitram | $67 | 3 payments
|
| Chiesi USA | Kengreal | $65 | 4 payments
|
| Astellas Pharma US | Lexiscan | $48 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $46 | 2 payments
|
| Alnylam Pharmaceuticals | Onpattro | $30 | 1 payment
|
| Boston Scientific | Resonate | $21 | 1 payment
|
| Daiichi Sankyo | Injectafer | $19 | 1 payment
|
| iRhythm Technologies | Zio Patch | $19 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $11 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 82.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1982625018
- Licence
- CA A63860California A63860: Current · expires 2027-11-30
- Group
- Sutter Bay Medical Foundation · Berkeley Cardiovascular Medical Group
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A638600
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 3300 Webster St, Suite 404-410, Oakland, CA, 94609
- NPI first listed
- 2006-07-22
- NPI last updated
- 2025-06-25
- NPI record certified
- 2025-06-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2450 Ashby Ave, Berkeley, CA, 94705